These ventures have been with Accelerate Cambridge for over a year, and have already raised a seed round.
PharmEnable explores new areas of chemical space that no one else is currently searching to enable the development of vital new medicines.
Visit the PharmEnable website
Stroke affects 16,000,000 people each year. 33 per cent of patients will die and 90 per cent of survivors will have a disability for the rest of their lives. POCKiT diagnostics have discovered a novel biomarker panel that could increase stroke patient treatment from 4 per cent to 40 per cent. We are leading a £1,000,000 grant from the United Kingdom government to finish an extensive clinical study in order to achieve regulatory approval. Our goal is to achieve market approval in 2020.
Visit the POCKiT diagnostics website
Qureight is a clinical data curation and analytics company which works in partnership with healthcare bodies and software developers in the field of artificial intelligence.
Through advanced infrastructure, coupled with technical and clinical expertise, the company performs annotation and analysis of anonymised data. Qureight exploits the value of data in their entirety and allows testing of machine learning algorithms, by collaborating with drug or technology companies, healthcare and academic institutions.
Qureight’s mission is to combine technology and life sciences to generate new knowledge and transform the way we use clinical data.
Spirea, a spin-out from the University of Cambridge, is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells resulting in greater efficacy and tolerability and the ability to treat more cancer patients.
Visit the Spirea website
Spotta intends to be the world leader in smart pest detection. Our core technology is an ultra-low-power, insect monitoring sensor that can detect infestations early. By allowing earlier, cheaper intervention we aim to put a significant dent in the global $70 billion annual cost of invasive insect pests.
Visit the Spotta website
Swift Molecular Diagnostics
Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.
We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.
Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips
Visit the Swift Molecular Diagnostics website